You searched for "Blindness"

984 results found

Differences of the anterior segment parameters in children with Down syndrome

This cross-sectional study was designed in order to demonstrate the differences in anterior segment parameters in children with trisomy 21. This is important as it may impact on surgical planning when undertaking procedures in the anterior segment such as corneal...

Outcomes of corneal collagen crosslinking (CXL) in pseudophakic bullous keratopathy (PBK)

This was a retrospective non-comparative, interventional case series of 50 eyes in 50 patients with symptomatic PBK who underwent CXL (epithelium-off). Central corneal thickness (CCT), pain score, best corrected visual acuity (BCVA), and corneal transparency were recorded at baseline; at...

A review of chromosome 9p21 POAG susceptibility locus

Primary open angle glaucoma (POAG) is a genetically complex disease and the overall phenotype is influenced by multiple traits including intraocular pressure (IOP), central corneal thickness and structural features of the optic nerve head. Therefore, genes affecting any of these...

Sutureless 27-gauge needle intrascleral intraocular lens implantation

The authors report on a prospective, non-comparative, interventional case series of patients undergoing sutureless intrascleral fixation of a posterior chamber three piece intraocular lens (IOL) using a 27-gauge needle for docking. Sutureless techniques have the advantage of not having complex...

Macular slippage following macular hole surgery

The treatment of macular holes now involves peeling the internal limiting membrane (ILM) as well as vitrectomy and gas tamponade. It has been noted in previous studies that following an ILM peel the morphology of the macula is different. Tadayoni...

Does Ozurdex affect perfusion status in vein occlusion?

Ozurdex (intravitreal dexamethasone implant) has been approved by National Institute of Health & Care Excellence (NICE) for treatment of patients with macular oedema associated with vein occlusion. This study looks at the change in peripheral perfusion status in patients with...

Outcomes of corneal cross-linking in paediatric patients compared to fellow untreated eyes

This retrospective cohort study evaluated long-term visual, refractive, topographic and safety outcomes of corneal cross-linking (CXL) in patients younger than 18-years-old with keratoconus. The study included all consecutive paediatric patients who underwent epithelium-off CXL treatment for keratoconus at the study...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Combined anti-VEGF and PDT for wet AMD

The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

RPE tears in cases of IPCV

The aim of this study was to investigate the occurrence, characteristics, management and prognosis of retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy (PCV). Medical records of previous cases were reviewed over an eight-year period from a...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...